ATE403736T1 - Onkolytische adenovirale vektoren - Google Patents

Onkolytische adenovirale vektoren

Info

Publication number
ATE403736T1
ATE403736T1 AT02714960T AT02714960T ATE403736T1 AT E403736 T1 ATE403736 T1 AT E403736T1 AT 02714960 T AT02714960 T AT 02714960T AT 02714960 T AT02714960 T AT 02714960T AT E403736 T1 ATE403736 T1 AT E403736T1
Authority
AT
Austria
Prior art keywords
adenoviral vectors
adenoviral
nucleic acid
viral vector
oncolytic adenoviral
Prior art date
Application number
AT02714960T
Other languages
English (en)
Inventor
David Ennist
Suzanne Forry-Schaudies
Mario Gorziglia
Paul Hallen-Beck
Carl Hay
John Jakubczak
Michael Kaleko
Patricia Ryan
David Stewart
Yuefeng Xie
Sheila Connelly
Seshidhar Reddy Police
Lori Clarke
Sandrina Phipps
Cheng Cheng
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Application granted granted Critical
Publication of ATE403736T1 publication Critical patent/ATE403736T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
AT02714960T 2001-02-23 2002-02-22 Onkolytische adenovirale vektoren ATE403736T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27092201P 2001-02-23 2001-02-23
US29503701P 2001-06-01 2001-06-01
US34867002P 2002-01-14 2002-01-14

Publications (1)

Publication Number Publication Date
ATE403736T1 true ATE403736T1 (de) 2008-08-15

Family

ID=27402327

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02714960T ATE403736T1 (de) 2001-02-23 2002-02-22 Onkolytische adenovirale vektoren

Country Status (8)

Country Link
US (1) US20030104625A1 (de)
EP (1) EP1377671B1 (de)
JP (1) JP2004529627A (de)
AT (1) ATE403736T1 (de)
CA (1) CA2439115A1 (de)
DE (1) DE60228066D1 (de)
IL (1) IL152420A0 (de)
WO (1) WO2002067861A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6492343B1 (en) * 1998-04-15 2002-12-10 University Of Saskatchewan Porcine adenovirus type 3 genome
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
US20030143200A1 (en) * 2001-09-24 2003-07-31 Tikoo Suresh K. Porcine adenovirus E1 region
CA2479759A1 (en) * 2002-03-22 2003-10-09 Board Of Regents, The University Of Texas System Protamine-adenoviral vector complexes and methods of use
JP3867968B2 (ja) * 2002-07-08 2007-01-17 関西ティー・エル・オー株式会社 腫瘍細胞において選択的に増殖する腫瘍融解ウイルス
US8163892B2 (en) * 2002-07-08 2012-04-24 Oncolys Biopharma, Inc. Oncolytic virus replicating selectively in tumor cells
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
US7371570B2 (en) 2002-11-01 2008-05-13 Cell Genesys, Inc. Cell-specific adenovirus vector comprising EBV-specific promoter
US20070099177A1 (en) * 2002-11-14 2007-05-03 Heim Albert R Agents and methods for detecting human adenoviruses
WO2004092397A2 (en) * 2003-04-15 2004-10-28 Novartis Ag Tmprss2 regulatory sequences and uses thereof
CA2526120A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
AU2003265873A1 (en) * 2003-08-28 2005-04-14 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
US20050097066A1 (en) * 2003-10-31 2005-05-05 Pitney Bowes Incorporated Method and system for a mailing machine to verify the integrity of printed postage
EP1718738A2 (de) 2004-02-23 2006-11-08 Crucell Holland B.V. Verfahren zur reinigung von viren
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
AU2005249586B2 (en) * 2004-06-04 2010-12-23 The Scripps Research Institute Compositions and methods for treatment of neovascular diseases
CN100361710C (zh) * 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
KR100756055B1 (ko) * 2006-01-27 2007-09-07 연세대학교 산학협력단 신생혈관 생성을 조절하는 재조합 아데노바이러스
CN100488568C (zh) * 2006-04-03 2009-05-20 南京师范大学 一种能分泌内皮抑素的细胞制剂及其在制备治疗肿瘤的药中的应用
WO2008108890A2 (en) * 2006-10-18 2008-09-12 University Of Rochester Conditionally replicating viruses for cancer therapy
EP1947463A1 (de) * 2007-01-16 2008-07-23 Roche Diagnostics GmbH Entnahme von flüssigen Analyseproben zum Zweck der klinischen Analyse
CN102448487B (zh) 2009-03-16 2016-03-16 麦克马斯特大学 疫苗接种方法
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
RS56741B1 (sr) 2009-11-13 2018-03-30 Daiichi Sankyo Europe Gmbh Materijal i postupci za lečenje ili prevenciju bolesti povezanih sa her-3
WO2012000188A1 (en) * 2010-06-30 2012-01-05 Tot Shanghai Rd Center Co., Ltd. Recombinant tumor vaccine and method of producing such
AU2011286407A1 (en) 2010-08-06 2013-02-21 Amgen Use of HER3 binding agents in prostate treatment
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
CN110917362A (zh) 2012-02-07 2020-03-27 全球生物疗法有限公司 核酸输送的区室化方法及其组合物和应用
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
AU2014221143B2 (en) 2013-02-21 2019-02-07 Turnstone Limited Partnership Vaccine composition
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
CN103555765B (zh) * 2013-05-30 2015-01-07 中南大学湘雅医院 一种转录调控肿瘤靶向复制溶瘤腺病毒载体、携带治疗基因腺病毒及其制备方法和应用
CA2920261C (en) 2013-08-08 2018-04-03 Global Bio Therapeutics, Inc. Clamp device for minimally invasive procedures and uses thereof
KR101901607B1 (ko) * 2015-09-01 2018-10-01 한양대학교 산학협력단 ＩＬ­12 및 ｓｈＶＥＧＦ 동시발현 아데노바이러스를 포함하는 항종양 면역성 증진 조성물
US10626413B2 (en) 2016-01-15 2020-04-21 Enyu Ding Nucleic acid vector
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2018183124A1 (en) * 2017-03-25 2018-10-04 Gen-Probe Incorporated Compositions, methods and kits to detect adenovirus, metapneumovirus and/or rhinovirus nucleic acids
JP7216668B2 (ja) * 2017-05-26 2023-02-01 エピセントアールエックス，インコーポレイテッド 導入遺伝子を保持する組換えアデノウイルス
WO2019048689A1 (en) 2017-09-11 2019-03-14 Imba - Institut Für Molekulare Biotechnologie Gmbh TUMOR ORGANOID MODEL
WO2021031551A1 (zh) 2019-08-19 2021-02-25 南京诺惟生物科技有限公司 一种调控脂质代谢的复制型溶瘤腺病毒及其应用
EP4340855A1 (de) 2021-08-13 2024-03-27 Triovance Holding LLC Hautersatzzusammensetzung und verfahren zur herstellung und verwendung davon
CN117568405A (zh) * 2023-11-14 2024-02-20 武汉凯德维斯生物技术有限公司 一种溶瘤腺病毒重组载体、构建方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5880102A (en) * 1995-01-17 1999-03-09 Duke University Adenoviral vector system
FR2763958A1 (fr) * 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
WO2000018903A2 (en) * 1998-09-29 2000-04-06 The Johns Hopkins University Inducible genetic suppression of cellular excitability
AU1523900A (en) * 1998-11-20 2000-06-13 Valentis, Inc. Adenoviral vector-mediated delivery of modified steroid hormone receptors and related products and methods
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
US7396679B2 (en) * 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus

Also Published As

Publication number Publication date
IL152420A0 (en) 2003-05-29
JP2004529627A (ja) 2004-09-30
US20030104625A1 (en) 2003-06-05
DE60228066D1 (de) 2008-09-18
EP1377671A2 (de) 2004-01-07
WO2002067861A3 (en) 2003-08-21
EP1377671B1 (de) 2008-08-06
WO2002067861A2 (en) 2002-09-06
CA2439115A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
ATE403736T1 (de) Onkolytische adenovirale vektoren
Ward et al. Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells.
AU696495B2 (en) Adenoviral vectors of animal origin and use in gene therapy
US10316065B2 (en) Oncolytic adenoviruses for treating cancer
EP0753068B1 (de) Adenovirusfaser mit hinzugefügten liganden
ATE332965T1 (de) Komplementierende zellinien
CA2229631A1 (en) Gene therapy using ovine adenoviral vectors
ATE470704T1 (de) Rekombinantes sendai-virus
WO2005005610A3 (en) Mutant adeno-associated virus virions and methods of use thereof
ES2170622A1 (es) Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
EP1854888A3 (de) Expressionsregulierende Sequenzen und Expressionsprodukte auf dem Gebiet der filamentösen Pilze
WO2000073478A3 (en) Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
Pearce et al. Glycoviruses: chemical glycosylation retargets adenoviral gene transfer
EP1015009A4 (de) abgeschwächte VIF DNA Immunisierungscassetten als genetische Impfstoffe
Duffy et al. Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
WO2004018627A3 (en) Methods for propagating adenovirus and virus produced thereby
WO2001044458A3 (en) Bovine immunodeficiency virus (biv) based vectors
WO2003029433A3 (en) Chimeric viral vectors for gene therapy
BR9609102A (pt) Construção de dna recombinante e vetor útil para produzir transformantes de células de hospedeiro bacteriano
Li et al. Adenovirus fiber shaft contains a trimerization element that supports peptide fusion for targeted gene delivery
WO2002008436A3 (en) Mini-adenoviral vector system for vaccination
WO2000066743A3 (en) Viral expression vectors
Knopf et al. The DNA replication origins of herpes simplex virus type 1 strain Angelotti
ENDOH et al. Expression and purification of recombinant Marek's disease virus serotype 1 specific phosphorylated protein pp38 in E. coli

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties